Ra Pharmaceuticals, Inc. (RARX) Stock: Seeing Declines In Today’s Session


Ra Pharmaceuticals, Inc. (RARX) is trending down in the market today. The stock, focused on the biotechnology space, is currently priced at $25.35 after tumbling -6.42% so far in today’s session. When it comes to biotech companies, there are a number of aspects that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines associated with RARX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-19 07:31AM Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar-04-19 07:00AM Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
Feb-28-19 07:00AM Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Feb-25-19 03:25PM 5 Clinical-Stage Biotech Stocks to Buy
Feb-21-19 07:00AM Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Nonetheless, when making an investing decision, prospective investors should take a look at much more than news, especially in the speculative biotech industry. Here’s what’s happing when it comes to Ra Pharmaceuticals, Inc..

Trends That We’ve Seen From RARX

While a move toward the top in a single session, like the move that we’re seeing from Ra Pharmaceuticals, Inc. might cause fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, invest in a stock. It is always a good idea to look into trends experienced by the stock beyond a single trading session. In the case of RARX, here are the returns that investors have seen:

  • Past 5 Trading Sessions – Throughout the past week, RARX has seen a change in price amounting to 7.80%.
  • Past 30 Days – The monthly performance from Ra Pharmaceuticals, Inc. works out to 35.11%.
  • Past Quarter – In the last quarter, the stock has generated a ROI of 66.30%
  • Past 6 Months – In the last six months, we’ve seen a performance that equates to 108.55% from the stock.
  • This Year So Far – Since the the last trading session of last year RARX has resulted in a ROI of 48.85%.
  • Full Year – Lastly, over the last year, we have seen performance amounting to 317.41% from RARX. Over this period, the stock has traded at a high of -8.42% and a low of 430.33%.

Ratios To Watch

Looking at a few key ratios associated with a stock can give prospective traders a look of just how dangerous and/or rewarding a stock pick might be. Below are some of the important ratios to consider when digging into RARX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it means that more investors believe that the value of the stock is going to go down. In general, biotech stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, in regard to Ra Pharmaceuticals, Inc., the stock’s short ratio comes to 3.52.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure whether or not a company can cover its debts as they mature using current assets or quick assets. Because many biotech many companies are reliant on continued support from investors, these ratios can be damning. However, some good picks in the biotechnology industry come with great quick and current ratios. When it comes to RARX, the quick and current ratios work out to 20.80 and 20.80 respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the share price of the stock. In this particular case, that ratio comes in at 6.05.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. In terms of RARX, the cash to share value ratio comes to 5.10.

How Analysts Feel About Ra Pharmaceuticals, Inc.

While it’s never a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their thoughts when validating your own before making an investment decision in the biotech industry. Below are the most recent moves that we have seen from analysts when it comes to RARX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-08-19 Initiated Stifel Buy $55
Oct-10-18 Upgrade Raymond James Outperform → Strong Buy
Jul-20-18 Initiated BMO Capital Markets Outperform $20
Jan-18-18 Resumed Credit Suisse Outperform $16
Sep-15-17 Initiated RBC Capital Mkts Outperform $21

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in RARX, here’s what we’re seeing:

Institutions own 95.90% of the company. Institutional interest has moved by 56.02% over the past three months. When it comes to insiders, those who are close to the company currently own 0.60% percent of RARX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Traders seem to have an interest in the amounts of shares both outstanding and available. In regard to Ra Pharmaceuticals, Inc., currently there are 41.16M and there is a float of 38.90M. These data mean that out of the total of 41.16M shares of RARX that are out there today, 38.90M are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to RARX, the short percent of the float is 4.26%.

What We’ve Seen In earnings results

What have ween seen from RARX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands, Wall St. analysts expect that the company will come up with EPS that comes to -2.27, with -0.48 being announced in the next financial report. Although this information isn’t based on earnings, because we’re chatting on the topic of Wall St. analysts, the stock is currently rated a 1.50 considering a scale that ranges from 1 to 5 where 1 is the poorest possible analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Over the last half decade, Ra Pharmaceuticals, Inc. has created a movement in sales volume in the amount of 0. EPS over the past 5 years have experienced a change of 0.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is generally explained in today’s society, the company has created a earnings change by 29.30%. RARX has also experienced movement when it comes to revenue that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here